

Distant Spread of Toxin Effect

Postmarketing reports indicate that the effects of MYOBLOC and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have occurred at doses comparable to those used to treat cervical dystonia and at lower doses. (See WARNINGS, PRECAUTIONS, and OVERDOSE sections of full Prescribing Information).

Important Safety Information

Myobloc® (rimabotulinumtoxinB) Injection is indicated for the treatment of adults with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia. Units of biological activity of MYOBLOC cannot be compared to or converted into units of any other botulinum toxin products.

Before administering MYOBLOC, physicians should consult the full Prescribing Information and Medication Guide. Note to representatives: Please provide full Prescribing Information and Medication Guide when presenting this material.

The most frequently reported adverse events with MYOBLOC are dry mouth, dysphagia, dyspepsia, and injection site pain. The vast majority of these adverse events were mild to moderate, temporary, self-resolving, and more common with higher doses. These adverse events may occur within the first week following treatment and may have a duration of several months. In controlled clinical trials, few patients (<1%) stopped treatment due to dry mouth or dysphagia. There is a reduced frequency of dry mouth and dysphagia reported with continued treatment. Dysphagia has commonly been reported by patients treated with all botulinum toxins for cervical dystonia.

Caution should be exercised when administering MYOBLOC to individuals with motor neuron disease (eg, amyotrophic lateral sclerosis), peripheral motor neuropathic diseases (eg, motor neuropathy) or neuromuscular junctional disorders (eg, myasthenia gravis or Lambert-Eaton syndrome). These patients may be at increased risk of clinically significant systemic effects including severe dysphagia and respiratory compromise from typical doses of MYOBLOC. In these patients, rare cases of dysphagia severe enough to cause aspiration pneumonia or to warrant the insertion of a gastric feeding tube have also been reported.

Coadministration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.



For more information about our Reimbursement Services and Patient Assistance Programs, or to obtain application forms, please call **1-888-461-2255** or visit our Web site at www.myobloc-reimbursement.com

SOLSTICE™
NEUROSCIENCES
www.solsticeneuro.com

Myobloc® is a registered trademark of Solstice Neurosciences, Inc.
© 2009 Solstice Neurosciences, Inc.
SNI-MYO398-0809

Reimbursement Support Program



MYOBLOC®
rimabotulinumtoxinB
Injection [5,000 Units/mL]
Service & Support

1-888-461-2255

8:00 AM - 7:00 PM Eastern Time Monday-Friday

www.myobloc-reimbursement.com

SOLSTICE™
NEUROSCIENCES

www.solsticeneuro.com

Reimbursement Services^a for MYOBLOC

Our reimbursement services team uses a case management approach and is available to facilitate the payment process for you and your staff.

Our staff will assist you in the following areas:

Insurance Verification

We will:

- Help validate patient insurance eligibility
- Help check medical and pharmacy benefits
- Help clarify copayments and deductibles

Prior Authorization

We will:

- Help identify prior authorization requirements
- Help facilitate submission of a prior authorization
- Provide a template letter of medical necessity for your completion
- Provide access to clinical information in support of claims upon your written request

Denials and Appeals

We will:

- Help research reason(s) for denied claims
- Help facilitate submission of the appeal
- Provide a template appeal letter upon your written request

MYOBLOC billing and coding information

Upon your written request, we will provide information on:

- General billing and coding for MYOBLOC
- J-Codes, ICD-9-CM^b, CPT^c and EMG codes
- Accurate claim filing
- Medicare Local Coverage Determinations (LCDs)
- Contact information for carriers and health plans

To obtain an enrollment form, please contact us at
1-888-461-2255 or visit our Web site at
www.myobloc-reimbursement.com

Patient Assistance Program (PAP)

Solstice Neurosciences, Inc. is dedicated to supporting the use of Myobloc[®] (rimabotulinumtoxinB) Injection for patients who are subject to financial hardship and who have a medically appropriate diagnosis as determined by medical professionals.

MYOBLOC is available at no charge for patients who:

- Are uninsured
- Are not covered by alternate sources of funding
- Meet specific clinical criteria established by Solstice
- Meet specific Federal Poverty Level guidelines

Solstice Neurosciences, Inc. sets the criteria for the Patient Assistance Program (PAP) and acceptance into the program at any time is not a guarantee that patients are entitled to receive assistance indefinitely.

Solstice Neurosciences, Inc. reserves the right at any time, and without notice: to modify any reimbursement forms; to modify or discontinue any or all of the aspects of the Program; or to terminate assistance under the Program at any time.

^a Reimbursement services are available only for those patients being treated with Myobloc[®] (rimabotulinumtoxinB) Injection for a therapeutic condition for which there is a reasonable expectation for reimbursement from a third-party payer. Physicians are responsible for identifying the clinical indication(s) and documenting medical necessity for any use of MYOBLOC. Questions regarding the clinical use of MYOBLOC should be directed to 1-888-461-2255.

^b ICD-9-CM codes are based on the World Health Organization (WHO) International Classification of Diseases, 9th edition. Solstice Neurosciences, Inc. assumes no liability for information contained herein. Solstice Neurosciences, Inc. claims no ownership or other interest in the ICD-9-CM codes.

^c CPT[®] codes are copyrighted property of the American Medical Association (AMA). Solstice Neurosciences, Inc. assumes no liability for any of the information contained herein. Solstice Neurosciences, Inc. claims no ownership or other interest in the CPT codes. CPT codes are provided herein for reference only and are not intended to convey any endorsement or sponsorship by, or affiliation with, the AMA.